Effect of skin graft with and without phototherapy in the treatment of acral vitiligo

Comparison of the additive effect of topical psoralen with ultraviolet A (PUVA) phototherapy after suction blister epidermal grafting surgery in patients with acral vitiligo

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140212016557N9

Enrollment

Registered

2021-10-07

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: Suction blister epidermal grafting surgery with topical psoralen with ultraviolet A (PUVA) phototherapy in one side hand or foot (Twice weekly for 6 months). Interv

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Acral vitiligo 18 years of age and higher Bilateral lesions Stable vitiligo in the past 6 months Ability to refer for phototherapy Minimum size of 1*1 cm Maximum size of 3*3 cm

Exclusion criteria

Exclusion criteria: History of keloid Treatment for vitiligo in the past one month Poor wound healing Consumption of anticoagulant drugs Consumption of immunosuppresant drugs Pregnancy Lactation

Design outcomes

Primary

Measure	Time frame
Reversal of normal skin pigment. Timepoint: Months 1, 2, 4, and 6. Method of measurement: Reverse Vitiligo Area Severity Index (VASI), which measures the percentage of pigment reversal.;Vitiligo Extent Score for a Target Area (VESTA). Timepoint: Months 1, 2, 4, and 6. Method of measurement: A formula that considers fully repigmented area, remaining area, and perifollicular repigmentation in the remaining area.	—

Measure

Time frame

Reversal of normal skin pigment. Timepoint: Months 1, 2, 4, and 6. Method of measurement: Reverse Vitiligo Area Severity Index (VASI), which measures the percentage of pigment reversal.;Vitiligo Extent Score for a Target Area (VESTA). Timepoint: Months 1, 2, 4, and 6. Method of measurement: A formula that considers fully repigmented area, remaining area, and perifollicular repigmentation in the remaining area.

—

Secondary

Measure	Time frame
Time of pigment reversal. Timepoint: Months 1, 2, 4, and 6. Method of measurement: Measurement of the numbers of weeks to achieve 50% pigment reversal.;Color match. Timepoint: Months 1, 2, 4, and 6. Method of measurement: Difference of the lesion color with surrounding normal skin color measured by colorimetric device.;Quality of Life. Timepoint: At the beginning and end of treatment. Method of measurement: Vitiligo Quality of Life index (VitiQoL).;Patient satisfaction. Timepoint: At the end of treatment. Method of measurement: Three questions with answers from 0 to 10.	—

Measure

Time frame

Time of pigment reversal. Timepoint: Months 1, 2, 4, and 6. Method of measurement: Measurement of the numbers of weeks to achieve 50% pigment reversal.;Color match. Timepoint: Months 1, 2, 4, and 6. Method of measurement: Difference of the lesion color with surrounding normal skin color measured by colorimetric device.;Quality of Life. Timepoint: At the beginning and end of treatment. Method of measurement: Vitiligo Quality of Life index (VitiQoL).;Patient satisfaction. Timepoint: At the end of treatment. Method of measurement: Three questions with answers from 0 to 10.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirhossein Heydarnejad

Shiraz University of Medical Sciences

amirhosseinheydarnejad@yahoo.com+98 712125239

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026